Cardiotoxicity risk in metastatic castration-resistant prostate cancer: enzalutamide versus abiraterone
Alan H. Bryce·Maelys Touya·David Nimke·Irene Varghese·Qiujun Shao·Pinal Kamdar·Jasmina Ivanova·Christopher Young·Nigel Rozario
Chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone (ABI) have a higher cardiovascular (CV) event-related hospitalization risk than those treated with enzalutamide (ENZA). This study aimed to assess CV event risk in chemotherapy-naïve patients with mCRPC treated with ENZA or ABI and to provide outcome data based on CV disease (CVD) history using the US Medicare database. Chemotherapy-naïve patients with mCRPC (≥ 65 years) who initiate